Last edition
News about "HERCULES Phase 3 Study"
EU Approves Sanofi's Cenrifki (Tolebrutinib) for Multiple Sclerosis
The European Commission (EC) has approved Sanofi’s Cenrifki (tolebrutinib) as the first disability-targeting treatment for adults with Secondary Progressive Multiple Sclerosis (SPMS) without relapses.
HERCULES Phase 3 Study | 25/06/2026 | By News Bureau | 189
Sanofi Reveals Positive Results of Tolebrutinib in HERCULES Phase 3 Study
In the HERCULES study, nrSPMS was defined at baseline as having an SPMS diagnosis with an expanded disability status scale (EDSS) score between 3.0 and 6.5, no clinical relapses for the previous 24 months and documented evidence of disability accumulation in the previous 12 months.
HERCULES Phase 3 Study | 03/09/2024 | By Aishwarya | 737
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy